餐后高血糖和心血管危險因素-全文預覽
【正文】 DM results suggest that acarbose can reduce the burden that type 2 diabetes places on individuals and society IGT: impaired glucose tolerance, STOPNIDDM: Study to Prevent Noninsulin Dependent Diabetes Mellitus 。45(Suppl. 2):A104. Hypertension* Myocardial infarction Any cardio vascular event p= p= p= 34% 91% 49% Reducing postprandial hyperglycaemia decreases the risk of diabetes and CVD STOP NIDDM Acarbose treatment resulted in a ? Relative risk reduction of 25% for the development of diabetes (p=)1 ? Relative risk reduction of 36% using two consecutive OGTTs (p=)1 ? 30% increase in the incidence of normal glucose tolerance (p)2 ? Statistically significant reduction in the risk of – hypertension – myocardial infarction – any cardiovascular event CVD: cardiovascular disease, OGTT: oral glucose tolerance test 1. Chiasson JL, et al. Diabetologia 2022。45(Suppl. 2):A104. Acarbose has a rapid and sustained effect on diabetes risk ? Acarboseassociated reduction in risk of diabetes was evident after 1 year ? Acarbose significantly reduced the risk of diabetes at each followup time point ? The beneficial effects of acarbose persisted for the duration of the trial ? Results of the STOPNIDDM show that acarbose has longterm therapeutic efficacy in individuals with IGT IGT: impaired glucose intolerance, STOPNIDDM: Study to Prevent Noninsulin Dependent Diabetes Mellitus Chiasson JL, et al, Lancet 2022。13:676–686 300 200 100 0 Plasma glucose (mg/dl) 0600 1200 1800 2400 0600 Time (hours) Mealtime glucose spikes Fasting hyperglycemia Normal C H D M O R T A LI T Y0510152025 6 .0 6 .1 7 .9 8H b A 1 cIncidence (%)A LL C H D E V E N T S0510152025 6 .0 6 .1 7 .9 8H b A 1 cIncidence (%)Kuusisto et al, 1994 Glycemic Control and CHD CHD Mortality All CHD Events A Comparison of Hba1c Levels Achieved in the Con
環(huán)評公示相關推薦
鄂ICP備17016276號-1